DEF 14A: Breeze Holdings Seeks Extension to Complete Business Combination, Sets Special Meeting

Breeze Holdings Acquisition Corp. is seeking stockholder approval to extend the deadline for completing a business combination by up to six months, with a special meeting scheduled for December 23, 2024.

Summary

• Breeze Holdings Acquisition Corp. is holding a special virtual meeting on December 23, 2024, to vote on proposals to extend the deadline for completing a business combination.
• The company is seeking to extend the deadline from December 26, 2024, by up to six months, potentially to June 26, 2025.
• This extension requires amending the company's charter and the Investment Management Trust Agreement.
• The company has entered into a merger agreement with YD Biopharma, with the transaction expected to close in the first quarter of 2025.
• If the extension is not approved, the company will liquidate, and public stockholders will receive a pro-rata share of the trust account, estimated to be approximately $11.26 per share.
• The company's sponsor will contribute $0.035 per public share for each month of the extension, up to six months, if the extension is approved.
• Stockholders can vote online, by phone, or by mail, and can also attend the virtual meeting.

Sentiment

Score: 5

Explanation: The document is neutral, outlining the need for an extension and the risks involved. While there is a merger agreement in place, the delisting from Nasdaq and the potential for liquidation temper any positive sentiment.

Positives

• The proposed extension provides additional time to complete the merger with YD Biopharma.
• The sponsor's contribution of $0.035 per share per month for the extension period adds to the trust account value.
• Stockholders have the option to redeem their shares if they do not support the extension.
• The company has a merger agreement in place with a target company, YD Biopharma, which is expected to close in the first quarter of 2025.

Negatives

• If the extension is not approved, the company will liquidate, and stockholders will receive a pro-rata share of the trust account, which may be less than the current trading price.
• The company was delisted from Nasdaq in July 2024 and now trades on the OTCQX, which may result in lower trading volume and price volatility.
• There is a risk that the merger with YD Biopharma may not be completed.
• The company may be subject to a 1% excise tax on redemptions.

Risks

• There is no guarantee that the extension will enable the company to complete a business combination.
• Redemptions in connection with the extension could leave the company with insufficient cash to complete a business combination.
• The company could be deemed an investment company, which would force liquidation.
• The delisting from Nasdaq may negatively impact the company's ability to raise capital and complete a merger.
• The merger with a U.S. target company could be subject to review by the Committee on Foreign Investment in the United States (CFIUS).
• A new 1% U.S. federal excise tax could be imposed on the Company in connection with redemptions.

Future Outlook

The company expects the transaction with YD Biopharma to close in the first quarter of 2025, subject to customary closing conditions.

Management Comments

• The Board believes that circumstances warrant providing public stockholders an opportunity to consider a business combination.
• The Board believes that, in order to be able to consummate an initial business combination, we will need to obtain the Extension and that, without the Extension, we would be forced to liquidate even if our stockholders are otherwise in favor of consummating an initial business combination.

Industry Context

The document reflects the challenges faced by special purpose acquisition companies (SPACs) in finding and completing business combinations within the initial timeframe, and the need for extensions to finalize deals.

Comparison to Industry Standards

• The need for an extension is not uncommon among SPACs, as many struggle to find suitable targets within the initial timeframe.
• The sponsor's contribution of $0.035 per share per month is a common mechanism to incentivize stockholders to approve an extension.
• The redemption rights offered to stockholders are standard practice in SPAC transactions.
• The delisting from Nasdaq and subsequent trading on OTCQX is a negative development, as it reduces liquidity and visibility, similar to other SPACs that have failed to meet listing requirements.

Stakeholder Impact

• Shareholders have the option to redeem their shares if they do not support the extension.
• If the extension is not approved, shareholders will receive a pro-rata share of the trust account.
• The company's delisting from Nasdaq may negatively impact investor confidence.
• Employees and customers may be affected by the company's financial condition and ability to complete a business combination.

Next Steps

• Stockholders will vote on the extension proposal at the special meeting on December 23, 2024.
• If the extension is approved, the company will continue to work towards completing the merger with YD Biopharma.
• The company will hold another stockholder meeting to seek approval of the business combination.

Key Dates

Keywords

business combination, special meeting, extension, merger, redemption, trust account, YD Biopharma, proxy statement, stockholders, liquidation